Kelvin Kinuthia Reacts To FDA Blindness Warning On Ozempic Surgery

Kenyan digital content creator Kelvin Kinuthia has reacted humorously to a new safety alert issued to users of popular weight-loss injections, including Ozempic and Mounjaro, over a rare eye condition linked to permanent vision loss.

Responding to a social media post detailing the advisory from the United States Food and Drug Administration (FDA), Kinuthia made light of the health warning with a witty remark.

“Eeiiyy nionge kwa kusimama ama kwa kuketi,” Kinuthia commented, sparking immediate engagement from followers familiar with his public weight-loss transformation.

Kinuthia’s Three-Year Weight-Loss Transformation

Kinuthia’s reaction drew widespread attention because he has openly documented his use of medical procedures and injectable treatments to shed weight over the past several years. On October 20, 2026, the creator shared before-and-after photos comparing his physique from October 2023 to October 2026, revealing that his weight had dropped from 148kg to 112kg.

Crediting local clinic Nure Aesthetics for supporting his recent progress, Kinuthia disclosed on October 5, 2026, that Mounjaro injections helped him lose 10kg within a single month, bringing him down from 125kg to 115kg. Prior to Mounjaro, he documented losing 5kg during his first week on Ozempic shots in May 2025, following an earlier gastric balloon procedure in 2022.

Understanding the FDA Warning on GLP-1 Medications

The FDA has instructed manufacturers of popular GLP-1 medications—including Ozempic, Wegovy, Mounjaro, and Zepbound—to update their safety labels to warn patients about nonarteritic anterior ischaemic optic neuropathy (NAION). This rare medical condition is caused by reduced blood flow to the optic nerve and can trigger sudden, painless vision loss, typically affecting one eye.

While clinical reviews noted a slightly higher rate of reported cases among GLP-1 users compared to control groups, regulators emphasized that the condition remains rare and does not affect the vast majority of patients. Users experiencing sudden vision changes, blurred eyesight, or blind spots are urged to seek immediate medical care, and patients are advised to consult their doctors before altering or discontinuing prescribed treatments.